Ultragenyx Pharmaceutical (NASDAQ: RARE ) provides a compelling case study in the rare disease space, moving from a development-stage biotech to a commercial entity with a pipeline that is poised for significant expansion. While the risks of biotechnologyI have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and forward-thinking enterprises. My approach is a mix of fund ...